CombiGene: Strategic consequences after CG01

Research update Q3 2024

2024-11-11

Implementing cost savings and new priorities
New propositions from the main shareholder
Our revised fair value estimate is SEK 8.27 (12.19) per share

In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again after reaching a return agreement with Spark Therapeutics. The company was also focused on developing the COZY programme for chronic pain. After evaluating the status of CG01, CombiGene decided to end the project and prioritise the COZY programme, with emphasis on the gene therapy COZY02. The company will also implement cost savings to prolong its financial runway. In Västra Hamnen’s webcast, CEO Peter Ekolind explained the reasons behind these decisions. Shortly after the webcast, the company’s largest shareholder proposed strategic changes, which shareholders will vote on in December. After a review, our estimated value is 8.27 SEK per share.

Read our latest research update below. The report is only available in English.

Download the report (pdf)

Martin Dominique

Chief Analyst

Tobias Karlsson

Analyst